Effect of recombinant human insulin-like growth factor-I on progression of ALS: A placebo-controlled study

Neurology

Volumn 49, Issue 6, 1997, Pages 1621-1630

  Lai, Eugene C ^a   Felice, K J ^b   Festoff, B W ^c   Gawel, M J ⁱ   Gelinas, D F ^d   Kratz, R ^e   Murphy, M F ^f   Natter, H M ^g   Norris, F H ^d   Rudnicki, S A ^h  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^d CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^e GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f CEPHALON INC   (United States)

^g HAHNEMANN UNIVERSITY HOSPITAL   (United States)

^h UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

ⁱ UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT SOMATOMEDIN C;

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM;

EID: 6844266272     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.49.6.1621     Document Type: Article

References (33)

1. Charcot JM. De la sclerose laterale amyotrophique: symptomatologie. Prog Med 1874;29:453-455.
2. Williams DB, Windebank AJ. Motor neuron disease (amyotrophic lateral sclerosis). Mayo Clin Proc 1991;66:54-82.
3. Norris F, Shepherd R, Denys E, et al. Onset, natural history and outcome in idiopathic adult motor neuron disease. J Neurol Sci 1993;118:48-55.
4. Rowland LP. Amyotrophic lateral sclerosis. Curr Opin Neurol 1994;7:310-315.
5. Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993;362:59-62.
6. Rowland LP. Amyotrophic lateral sclerosis: human challenge for neuroscience. Proc Nat Acad Sci USA 1995;92: 1251-1253.
7. Brown RH Jr. Amyotrophic lateral sclerosis: recent insights from genetics and transgenic mice. Cell 1995;80:687-692.
8. Bowling AC, Schulz JB, Brown RH Jr, Beal MF. Superoxide dismutase activity, oxidative damage, and mitochondrial energy metabolism in familial and sporadic amyotrophic lateral sclerosis. J Neurochem 1993;61:2322-2325.
9. Rothstein JD, Martin LJ, Kuncl RW. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N Engl J Med 1992;326:1464-1468.
10. Smith RG, Appel SH. Molecular approaches to amyotrophic lateral sclerosis. Annu Rev Med 1995;46:133-145.
11. Lewis ME, Vaught JL, Neff NT, et al. The potential of insulin-like growth factor-I as a therapeutic for the treatment of neuromuscular disorders. Ann NY Acad Sci 1993; 692:201-208.
12. Neff NT, Prevette D, Houenou LJ, et al. Insulin-like growth factors: putative muscle-derived trophic agents that promote motoneuron survival. J Neurobiol 1993;24:1558-1566.
13. Caroni P. Activity-sensitive signals by muscle-derived IGFs in the development and regenerating neuromuscular system. Ann NY Acad Sci 1993;692:209-222.
14. Caroni P, Grandes P. Nerve sprouting in innervated adult skeletal muscle induced by exposure to elevated levels of insulin-like growth factors. Cell Biol 1990;110:1307-1317.
15. Hanta D, Akaaboune M, Lagord C, et al. Beneficial effects of insulin-like growth factor-I on Wobbler mouse motoneuron disease. J Neurol Sci 1995;129(suppl):130-139.
16. Adem A, Ekblom J, Gillberg P-G, et al. Insulin-like growth factor-I receptors in human spinal cord: changes in amyotrophic lateral sclerosis. J Neurol Transm 1994;97:73-84.
17. Dore S, Krieger C, Kar S, Quirion R. Distribution and levels of insulin like growth factor (IGF-I and IGF-II) and insulin receptor binding sites in the spinal cords of amyotrophic lateral sclerosis (ALS) patients. Mol Brain Res 1996;41(1-2):128-132.
18. Guler HP, Wettstein K, Schurr W, Zapf J, Froesch ER. Recombinant human insulin-like growth factor I: effects in normal subjects and implications for use in patients. In: Raizada MK, LeRoith D, eds. Molecular biology and physiology of insulin and insulin-like growth factors. New York: Plenum Press, 1991:97-104.
19. Festoff BW, Yang SX, Stong D. Strategies for the use of recombinant human growth hormone and insulin-like growth factor I in amyotrophic lateral sclerosis. In: Blackman MR, Harman SM, Roth J, Shapiro JR, eds. Growth hormone releasing hormone, growth hormone and IGF-I: basic and clinical advances. New York: Springer-Verlag, 1995:110-128.
20. Subcommittee on Motor Neuron Disease/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Disease, El Escorial "Clinical Limits of Amyotrophic Lateral Sclerosis" Workshop contributors. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 1994; 124(suppl):96-107.
21. Appel V, Stewart SS, Smith G, Appel SH. A rating scale for amyotrophic lateral sclerosis: description and preliminary experience. Ann Neurol 1987;22:328-333.
22. Haverkamp LJ, Appel V, Appel SH. Natural history of amyotrophic lateral sclerosis in a database population: validation of a scoring system and a model for survival prediction. Brain 1995;118:707-719.
23. Bergner M, Bobbit RA, Carter WB, Gilson BS. The sickness impact profile: development and final revision of a health status measure. Med Care 1981;19:787-805.
24. McGuire D, Garrison L, Armon C, et al. Relationship of the Tufts Quantitative Neuromuscular Exam (TQNE) and the sickness impact profile (SIP) in measuring progression of ALS. Neurology 1996;46:1442-1444.
25. SAS Institute, Inc. SAS/STAT users guide. Version 6, 4th ed., vol. 2. Cary, NC: SAS Institute Inc., 1989:1351-1456.
26. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Am Stat Assoc J 1958;53:457-481.
27. Cox DR. Regression models and life-tables. J R Stat Soc [Br] 1972;34:187-220.
28. Appel SH, Stewart SS, Appel V, et al. A double-blind study of the effectiveness of cyclosporine in amyotrophic lateral sclerosis. Arch Neurol 1988;45:381-386.
29. Lange DJ, Murphy PL, Diamond B, Younger DS, Appel SH, Appel V. A double-blind placebo-controlled study to assess the effect of deprenyl on the clinical course of ALS [abstract]. Neurology 1994;44(suppl 2):A256.
30. Bensimon G, Lacomblez L, Meininger V, ALS/Riluzole Study Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994;330:585-591.
31. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V, ALS/Riluzole Study Group II. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 1996;347:1425-1431.
32. Stalberg E. Electrophysiological studies of reinnervation in ALS. In: Rowland LP, ed. Human motor neuron diseases. New York: Raven Press, 1982:47-59.
33. Lewis ME, Neff NT, Contreras PC, et al. Insulin-like growth factor-I: potential for treatment of motor neuronal disorders. Exp Neurol 1993;124:73-88.